YOLFTbeta
Jade Biosciences, Inc.

Jade Biosciences, Inc.

JBIO · NASDAQ · Healthcare / Biotechnology

16.14USD+0.27 (+1.70%)

Price History

Full chart

Market Stats

Previous Close15.87
Open16.23
Day Range15.58 – 16.34
52-Week Range8.16 – 28.00
Volume593.50K
Market Cap912.62M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.06
Dividend Yield0.00%
50-Day Avg19.93
200-Day Avg18.34

About

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Tom Frohlich
  • Employees55
  • HeadquartersBuilding 23, Waltham, MA, United States, 02453, USA
  • Websitehttps://jadebiosciences.com

Leadership

  • Mr. Tom FrohlichPresident, CEO & Director · b. 1976
  • Mr. Bradford D. Dahms Ph.D.CFO & Treasurer · b. 1989
  • Dr. Andrew James King BVMS, D.V.M., Ph.D.President of Research & Development · b. 1980
  • Ms. Elizabeth Balta J.D.Chief Legal Officer & Corporate Secretary · b. 1971
  • Ms. Lori StewartSenior Vice President of People
  • Mr. Jonathan QuickSenior Vice President of Finance
  • Ms. Valerie FauvelleSenior Vice President of Regulatory & Quality
  • Ms. Amy SullivanSenior Vice President of Development Operations
  • Ms. Sandy LewisSenior Vice President, Biometrics & Clinical Strategy
  • Dr. Edward R. Conner M.D.Chief Medical Officer · b. 1973

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----0
Cost of Revenue1.00K15.00K68.00K96.00K282.00K26.00K
Gross Profit-1.00K-15.00K-68.00K-96.00K-282.00K-26.00K
Operating Expense8.89M23.01M53.17M81.31M74.31M113.52M
Operating Income-8.89M-23.02M-53.24M-81.41M-74.60M-113.54M
EBITDA-9.54M-22.95M-51.42M-75.37M-69.29M-127.33M
Net Income-9.61M-22.96M-51.51M-75.52M-69.63M-127.41M
R&D7.94M14.99M38.62M64.22M53.19M93.12M
Interest Expense75.00K-----

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.71M175.36M135.30M127.42M80.33M349.78M
Total Liabilities1.77M2.94M8.56M17.96M3.90M17.26M
Total Equity2.94M172.42M126.74M109.46M76.43M332.52M
Cash4.57M54.20M22.40M23.49M33.75M88.44M
Total Debt-574.00K1.09M675.00K417.00K724.00K
Net Debt-4.57M-53.62M-21.31M-22.82M-33.33M-87.71M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.86M-27.40M-39.12M-56.78M-71.20M-94.69M
Investing Cash Flow--113.43M6.93M11.88M56.03M-247.01M
Financing Cash Flow8.92M190.46M396.00K46.00M25.43M360.77M
Capital Expenditure0181.00K195.00K142.00K0196.00K
Free Cash Flow-7.86M-27.58M-39.32M-56.92M-71.20M-94.89M
FCF to OCF100.00%100.66%100.50%100.25%100.00%100.21%

Earnings

Report DateMay 6, 2021Aug 16, 2021Nov 15, 2021Mar 30, 2022May 16, 2022Aug 17, 2022Nov 14, 2022Mar 29, 2023May 16, 2023Aug 14, 2023Nov 13, 2023Mar 25, 2024May 13, 2024Aug 12, 2024Nov 11, 2024Mar 26, 2025May 14, 2025Aug 13, 2025Nov 12, 2025Dec 31, 2025May 7, 2026Aug 10, 2026Nov 12, 2026
EPS Estimate-0.62-23.80-0.26-0.33-0.45-0.49-0.50-0.61-0.57-0.70-0.69-0.74-0.76-0.85-0.58-0.40-2.05-0.48-0.67-0.47-0.48-0.66-0.73
EPS Actual-12.77-833.00-9.10-11.90-15.75-17.15-0.56-21.35-0.67-0.76-0.71-25.90-0.83-30.10-19.60-6.61-12.10-0.86-0.48--0.57-0.76-
Surprise-1959.68%-3400.00%-3400.00%-3506.06%-3400.00%-3400.00%-12.00%-3400.00%-17.54%-8.57%-2.90%-3400.00%-9.21%-3441.18%-3274.66%-1542.24%-490.24%-79.17%28.36%--18.75%-15.15%-
Timing----------------After-hoursAfter-hoursAfter-hours-After-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap912.62M
Enterprise Value473.67M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.12
EPS-1.06
Book Value6.92
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-164.70M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-89.19%
Return on Assets-33.59%
Shares Outstanding63.60M
Shares Float51.97M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 3 analystsTarget 50.13
  • Strong Buy
    3

Ownership Breakdown

Institutions
116.07%
Insiders
0.79%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    7.09M11.14%
  • Fairmount Funds Management LLC
    4.55M7.16%
  • RA Capital Management, LLC
    3.67M5.77%
  • Bellevue Group AG
    3.50M5.51%
  • VR Adviser, LLC
    3.22M5.06%
  • HHG PLC
    3.11M4.88%
  • Paradigm Biocapital Advisors LP
    2.86M4.49%
  • BlackRock Inc
    2.31M3.64%
  • Adage Capital Partners Gp LLC
    1.91M3.00%
  • Vanguard Capital Management, LLC
    1.80M2.83%
  • Avidity Partners Management LP
    1.70M2.67%
  • Baker Bros Advisors LP
    1.64M2.58%
  • Remedium Capital Partners, LLC
    1.58M2.48%
  • Soleus Capital Management, L.P.
    1.55M2.44%
  • Logos Global Management LP
    1.13M1.77%

Top Fund Holders

  • Polar Capital Biotech S Inc
    1.75M2.75%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.70M2.67%
  • Franklin Small Cap Value A
    1.63M2.56%
  • State Street® SPDR® S&P® Biotech ETF
    1.62M2.54%
  • Fidelity Growth Company Fund
    1.19M1.87%

Dividends

20251×
2.40Apr 29, 2025

Stock Splits

  • Apr 29, 20251:35